179 related articles for article (PubMed ID: 20190418)
1. Development of liposomal salbutamol sulfate dry powder inhaler formulation.
Huang WH; Yang ZJ; Wu H; Wong YF; Zhao ZZ; Liu L
Biol Pharm Bull; 2010; 33(3):512-7. PubMed ID: 20190418
[TBL] [Abstract][Full Text] [Related]
2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
[TBL] [Abstract][Full Text] [Related]
4. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
5. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961
[TBL] [Abstract][Full Text] [Related]
6. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
[TBL] [Abstract][Full Text] [Related]
7. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
[TBL] [Abstract][Full Text] [Related]
8. [Effect of separation characteristics between salbutamol sulfate (SS) particles and model carrier excipients on dry powder for inhalation].
Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Danjo K
Yakugaku Zasshi; 1999 Oct; 119(10):752-62. PubMed ID: 10518459
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
10. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
Hoe S; Traini D; Chan HK; Young PM
Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
12. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
13. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
Ooi J; Gill C; Young PM; Traini D
Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438
[TBL] [Abstract][Full Text] [Related]
14. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
15. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
[TBL] [Abstract][Full Text] [Related]
16. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
17. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
Srichana T; Martin GP; Marriott C
Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
[TBL] [Abstract][Full Text] [Related]
18. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
Zeng XM; Martin GP; Tee SK; Ghoush AA; Marriott C
Int J Pharm; 1999 May; 182(2):133-44. PubMed ID: 10341303
[TBL] [Abstract][Full Text] [Related]
19. The role of force control agents in high-dose dry powder inhaler formulations.
Begat P; Morton DA; Shur J; Kippax P; Staniforth JN; Price R
J Pharm Sci; 2009 Aug; 98(8):2770-83. PubMed ID: 19067395
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
